Literature DB >> 22905341

Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients.

Heather Sl Jim1, Tim D Boyd, Margaret Booth-Jones, Joseph Pidala, Huntington Potter.   

Abstract

BACKGROUND: Endogenous Granulocyte Macrophage Colony Stimulating Factor (GMCSF) is released in rheumatoid arthritis patients, who are largely protected from Alzheimer's disease (AD). Introducing exogenous GMCSF into an AD mouse model reduced amyloid deposition by 55% and restored normal cognition. No published studies have examined exogenous GMCSF and cognitive functioning in humans. OBJECTIVES/
DESIGN: The goal of the current study was to examine the association between receipt of GMCSF and cognitive functioning in patients receiving colony stimulating factors as part of routine supportive care for hematopoietic cell transplantation (HCT). SETTING AND PARTICIPANTS: Archived neuropsychological data were examined from a longitudinal study of cognitive functioning in 95 patients receiving HCT at the Moffitt Cancer Center. INTERVENTION: Receipt of GMCSF and/or Granulocyte Colony Stimulating Factor (GCSF) was ascertained through patient billing records. MEASUREMENTS: Patients were assessed with a battery of neuropsychological tests prior to transplant and 6 and 12 months post-transplant.
RESULTS: Patients treated with GMCSF and GCSF (n=19) showed significantly greater improvement in total neuropsychological functioning (TNP) at 6 months than patients treated with GCSF only (n=76) (p=.04). There was no group difference in TNP at 12 months (p=.24). Improvement in TNP from baseline to 6 months post-HCT was significant in the GMCSF+GCSF group (p=.01) but not the GCSF only group (p=.33). Improvement in TNP from baseline to 12 months post-HCT was significant in both groups (ps<.01).
CONCLUSION: Preliminary data from this study of humans receiving colony stimulating factors suggest that receipt of GMCSF+GCSF was associated with greater cognitive improvement than GCSF alone. Randomized controlled trials of the effects of GMCSF on cognitive functioning in humans are warranted and underway to confirm these findings.

Entities:  

Year:  2012        PMID: 22905341      PMCID: PMC3422132          DOI: 10.4172/bdt.1000101

Source DB:  PubMed          Journal:  Brain Disord Ther        ISSN: 2168-975X


  25 in total

Review 1.  The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation.

Authors:  H Potter; I M Wefes; L N Nilsson
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

2.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

Authors:  Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan
Journal:  Arch Neurol       Date:  2008-05-12

Review 3.  Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years.

Authors:  Patrick L McGeer; Joseph Rogers; Edith G McGeer
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

4.  Prospective evaluation of neurological complications after allogeneic bone marrow transplantation.

Authors:  P Sostak; C S Padovan; T A Yousry; G Ledderose; H-J Kolb; A Straube
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

5.  The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells.

Authors:  Ali Jalili; Neeta Shirvaikar; Leah A Marquez-Curtis; A Robert Turner; Anna Janowska-Wieczorek
Journal:  Stem Cells Dev       Date:  2010-08       Impact factor: 3.272

6.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

7.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-beta.

Authors:  S H Zuckerman; G F Evans; L O'Neal
Journal:  Atherosclerosis       Date:  1992-10       Impact factor: 5.162

9.  Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.

Authors:  J Sanchez-Ramos; S Song; V Sava; B Catlow; X Lin; T Mori; C Cao; G W Arendash
Journal:  Neuroscience       Date:  2009-06-14       Impact factor: 3.590

10.  Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.

Authors:  Vincent Boissonneault; Mohammed Filali; Martine Lessard; Jane Relton; Gordon Wong; Serge Rivest
Journal:  Brain       Date:  2009-01-17       Impact factor: 13.501

View more
  12 in total

1.  pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.

Authors:  Pete Heinzelman; Jennifer A Schoborg; Michael C Jewett
Journal:  Protein Eng Des Sel       Date:  2015-04-15       Impact factor: 1.650

Review 2.  Colony stimulating factors in the nervous system.

Authors:  Violeta Chitu; Fabrizio Biundo; E Richard Stanley
Journal:  Semin Immunol       Date:  2021-11-04       Impact factor: 11.130

3.  The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice.

Authors:  Md Mahiuddin Ahmed; Athena Ching-Jung Wang; Mihret Elos; Heidi J Chial; Stefan Sillau; D Adriana Solano; Christina Coughlan; Leila Aghili; Paige Anton; Neil Markham; Vanesa Adame; Katheleen J Gardiner; Timothy D Boyd; Huntington Potter
Journal:  Neurobiol Dis       Date:  2022-03-18       Impact factor: 7.046

4.  Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.

Authors:  Grace E Weber; Maria Khrestian; Elizabeth D Tuason; Yvonne Shao; Jagan Pillai; Stephen Rao; Hao Feng; Yadi Zhou; Feixiong Cheng; Tara M DeSilva; Shaun Stauffer; James B Leverenz; Lynn M Bekris
Journal:  J Immunol       Date:  2022-05-06       Impact factor: 5.426

Review 5.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

6.  Role of granulocyte macrophage colony stimulating factor in regeneration of the central nervous system.

Authors:  Ushananthini Shanmugalingam; Nafisa M Jadavji; Patrice D Smith
Journal:  Neural Regen Res       Date:  2016-06       Impact factor: 5.135

7.  Insights into the protective role of immunity in neurodegenerative disease.

Authors:  Cristoforo Comi; Giacomo Tondo
Journal:  Neural Regen Res       Date:  2017-01       Impact factor: 5.135

8.  Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19.

Authors:  Huntington Potter; Timothy D Boyd; Penny Clarke; Victoria S Pelak; Kenneth L Tyler
Journal:  F1000Res       Date:  2020-05-11

9.  Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.

Authors:  Huntington Potter; Jonathan H Woodcock; Timothy D Boyd; Christina M Coughlan; John R O'Shaughnessy; Manuel T Borges; Ashesh A Thaker; Balaibail A Raj; Katarzyna Adamszuk; David Scott; Vanesa Adame; Paige Anton; Heidi J Chial; Helen Gray; Joseph Daniels; Michelle E Stocker; Stefan H Sillau
Journal:  Alzheimers Dement (N Y)       Date:  2021-03-24

Review 10.  Peripheral immune system in aging and Alzheimer's disease.

Authors:  Wei Cao; Hui Zheng
Journal:  Mol Neurodegener       Date:  2018-10-03       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.